Gerhard Gebauer: Current findings on systemic therapy for endometrial cancer at ESGO Annual Meeting
Gerhard Gebauer, Chief Physician at Asklepios Clinics International, posted on LinkedIn:
“ESGO Annual Meeting in Rome: Current findings on systemic therapy for endometrial cancer.
At this year’s ESGO Congress in Rome, Prof. Christian Marth presented data on the relevance of p53 expression for systemic therapy of endometrial cancer. The focus was on the results of the RUBY-2 and DUO-E studies as well as current data on selinexor, which underline the potential of personalized treatment approaches.
Key messages of the lecture:
- p53 expression proves to be a crucial biomarker for therapy decisions.
- The combination of immune checkpoint inhibitors and chemotherapy shows promising results, especially in p53-wt tumors.
- The latest data from the RUBY-2 and DUO-E studies indicate a significant improvement in progression-free survival – a significant step towards precision medicine approaches.
- Selinexor, a selective inhibitor of nuclear export (SINE), shows promising efficacy in advanced endometrial cancer. Especially in patients with p53 mutations, selinexor seems to suppress tumor growth and increase the response rate by inhibiting the export protein XPO1.
These findings could significantly change clinical practice by enabling the identification of patients who particularly benefit from innovative therapy combinations.
What do these advances mean for the future of gynaecological oncology? Feel free to discuss in the comments!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023